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Summary
Six families with mosaicism are identified in a series of
62 unrelated families with a mutation in one of the two
tuberous sclerosis complex (TSC) genes, TSC1 or TSC2.
In five families, somatic mosaicism was present in a
mildly affected parent of an index patient. In one family
with clinically unaffected parents, gonadal mosaicism
was detected after TSC was found in three children. The
detection of mosaicism has consequences for genetic
counseling of the families involved, as changed risks ap-
ply to individuals with mosaicism, both siblings and par-
ents. Clinical investigation of parents of patients with
seemingly sporadic mutations is essential to determine
their residual chance of gonadal and/or somatic mosa-
icism, unless a mosaic pattern is detected in the index
patient, proving a de novo event. In our data set, the
exclusion of signs of TSC in the parents of a patient
with TSC reduced the chance of one of the parents to
be a (mosaic) mutation carrier from 10% to 2%. In the
five families with somatic mosaicism, the parent was
given the diagnosis after the diagnosis was made in the
child.
Introduction
Tuberous sclerosis complex (TSC) is an autosomal dom-
inant, hereditary disease, characterized by the growth of
hamartomas and hamartias that can occur in almost all
tissues. Most lesions occur in the brain (subependymal
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nodules or giant cell astrocytomas, or subcortical and
cortical tubers), in the skin (facial angiofibromas, white
macules, shagreen patches, or ungual fibromas), in the
kidneys (cysts and angiomyolipomas), in the heart (rhab-
domyomas), and in the eyes (retinal hamartomas). Pa-
tients with severe disease suffer from epilepsy (found in
60%–70% of patients with TSC) andmental retardation
(found in ∼40%–50% of patients with TSC). Mortality
due to TSC is mostly from two complications: (1) renal
bleeding from an angiomyolipoma or (2) the develop-
ment of an intracerebral giant cell astrocytoma. The
prevalence of TSC is estimated at ∼1/10,000 births.
More than half the patients with TSC represent sporadic
cases, reflecting a high mutation frequency, estimated at
2.5/10,000/gene in each generation (Sampson et al.
1989).
TSC is caused by a mutation in either the TSC1 gene,
located on chromosome 9 (MIM 191100), or the TSC2
gene, on chromosome 16 (MIM 191092). After both
genes were characterized, the identification of mutations
became feasible. Mutation analysis for both genes re-
veals that most families have a unique mutation, al-
though recurrent mutations have been described (van
Slegtenhorst et al. 1997, 1999; Au et al. 1998; Verhoef
et al. 1998). Mutation detection has provided an op-
portunity to study possible relationships between ge-
notype and phenotype, to investigate presumed de novo
mutations, and, occasionally, to provide diagnostic cer-
tainty in individuals with a particularly mild clinical
phenotype.
Reports of “apparent nonpenetrance” in TSC, with
multiple offspring of clinically unaffected parents, sug-
gested that parental mosaicism could be expected, as had
been suggested by Hall and Byers (1987). Several ex-
amples of somatic (Verhoef et al. 1995; Sampson et al.
1997) and gonadal (Yates et al. 1997) mosaicism in TSC
have been reported.
We present six families in which mosaicism was de-
tected in a group of 62 unrelated families with TSC with
a known mutation (from our study population of 225
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Table 1
Oligonucleotides for Amplification of Exons and
Introns for SSCP Analysis and for ASO
Hybridization
Method, Gene, and































families). All five individuals with somatic mosaicism
had mild phenotypic features of TSC; in one family the
mosaicism was proved to be gonadal and, possibly, so-
matic as well. Clinical data on the affected individuals
in the families are presented.
Subjects and Methods
The present study was approved by theMedical Ethics
Committee of the Academic Hospital Rotterdam
Dijkzigt.
Subjects
Clinical data and blood samples from patients with
TSC have been collected since 1987. Data from a total
of 350 individuals with TSC from 225 unrelated families
have been entered in a clinical registry.Mutation analysis
is generally performed with the use of DNA from the
index patients of each family. Details of the affected
family members presented in this paper are discussed in
the Results section.
Methods
Mutation analysis was undertaken in 225 unrelated
patients with TSC. The DNA of affected individuals (and
parents, when available) was isolated from peripheral
leukocytes obtained by venipuncture. Mutation analysis
of the TSC1 gene consisted of SSCP analysis of all coding
exons. Primer sequences used for the amplification re-
actions are those described by van Slegtenhorst et al.
(1999). Direct-sequence analysis was performed accord-
ing to standard methods. For the identification of mu-
tations in the TSC2 gene, Southern blotting was used to
detect large-size abnormalities, followed by SSCP anal-
ysis for all coding exons (still in progress). Relevant
primer sequences are given in table 1; the other exon
primers are used as published elsewhere (Au et al. 1998).
Southern blotting was done according to standard
procedures by means of genomic DNA digested with the
restriction enzymes HindIII and EcoRI. Probes used for
analysis of large deletions in the TSC2 gene were 4B2,
4.9E0.7, and 1A1 (The European Chromosome 16 Tu-
berous Sclerosis Consortium 1993).
Oligonucleotides were designed for the normal and
the mutated sequences (table 1). Allele-specific oligon-
ucleotide (ASO) hybridizations were performed on du-
plicate filter sets at 37C for 30 min. Filters were washed
in for 10 min at 37C.0.3# SSC
For haplotype analysis in family 2, flanking markers
were used on chromosome 9: D9S2126 and D9S1830,
proximal to TSC1; D9S1199 and D9S1198, distal to the
gene (Van Slegtenhorst et al. 1997). Reverse-transcrip-
tion (RT)-PCR analysis for family 4 was done on total
RNA from fibroblast cells of the index patient according
to standard procedures. The primers used in the RT-PCR
reaction were forward 5′-GCAAAGATTCAGGCTT-
GAAGG-3′ (exon 1) and 5′-CCACATTCCATGCT-
CAGT-3′ (exon 2). Direct-sequence analysis was per-
formed on the isolated aberrant RT-PCR product with
the same primers. Families were tested to confirm family
structure with the Profiler Plus Kit (Perkin-Elmer),which
contains nine highly polymorphic markers from nine dif-
ferent chromosomes.
Results
After mutation analysis of the complete coding region
of the TSC1 gene, Southern blotting for the TSC2 gene,
and SSCP analysis of ∼25% of the coding region of the
TSC2 gene, 29 mutations were detected in TSC1 and
33 mutations were detected in TSC2. In five of the 62
families, parental somatic mosaicism could be proved.
In the sixth family, occurrence of TSC in three sibs with
clinically unaffected parents was consistent with germ-
line mosaicism, as no somatic copies could be detected
in the parents (fig. 1).
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Figure 1 Six families with TSC showing mosaicism. From left to right are TSC1 mutations 942insA and 1473delC and TSC2 mutations
2374-2ArC (all are dot blots of ASO hybridization analysis), 1561GrA (slot blot of ASO hybridization analysis), a deletion of 1.5 kb (probe
4.9E0.7), and a deletion of unknown size (probe 4B2), on Southern blot analysis. In each pedigree, squares denotes males, circles denote females,
and diamonds denote individuals whose sex is not indicated (for purposes of confidentiality); in each pedigree, the person with mosaicism is
denoted by the hatched symbols. NC  negative control sample.
Mosaicism for Mutations in the TSC1 Gene
Family 1 (T4715).—A boy had epilepsy, mental retar-
dation, facial angiofibroma, ungual fibroma, white mac-
ules, a shagreen patch, and gingival fibromas. Cortical
tubers and subependymal nodules were visible on the
CT scan. His mother had normal intelligence and no
epilepsy, but, when examined, was found to have facial
angiofibroma, white macules, and a shagreen patch on
the skin. A CT scan of the mother’s brain showed su-
bependymal nodules. SSCP analysis showed an abnor-
mal pattern of exon 8 of the TSC1 gene. Direct-sequence
analysis resulted in the identification of a frameshift mu-
tation 942insA (Van Slegtenhorst et al. 1999). ASO hy-
bridization analysis showed that the ratio of the mutant-
to-normal allele was less in the DNA of the mother than
in that of her son.
Family 2 (T10301).—The index patient was 9 years
old, the sixth child in a large family. His medical history
revealed congenital cardiac tumors, detected antenatally
with ultrasound after analysis of irregular fetal heart
rhythm. The tumors had regressed with age. At age 8
years, myoclonic epilepsy occurred. White macules were
then noted on the skin. On the basis of these findings,
together with the congenital heart tumors (most prob-
ably rhabdomyomas), a clinical diagnosis of TSC was
made. A CT scan of the brain showed subependymal
nodules and confirmed the diagnosis. The youngest sib-
ling developed epilepsy at age 2 years and had three
hypopigmented macules on the skin. A CT scan showed
subependymal nodules and an irregular cortical gyration
pattern, demonstrative of TSC. Both parents were pre-
sumed to be unaffected (by skin examination only; they
had no history of epilepsy or learning difficulties). SSCP
analysis of the TSC1 gene in the index patient in this
family showed an abnormal pattern of exon 12. Direct
sequencing followed by ASO hybridization analysis
showed a frameshift mutation 1473delC (Van Slegten-
horst et al. 1999). Subsequent analysis of DNA from the
complete family with ASO hybridization analysis iden-
tified the mutation in both clinically affected children
and in a third sib, aged 10 years, suspected of having
TSC because of developmental delay and possibly the
beginning of a facial angiofibroma. The mutation could
not be detected in DNA from blood cells of the parents,
suggesting mosaicism. Using flanking markers to the
TSC1 gene, we performed haplotyping of the parents
and all children. In addition to the three affected chil-
dren, two more children were shown to carry the af-
fected allele without the mutation, proving gonadal mo-
saicism in one of the parents (results not shown). Because
the parents do not wish to know their carrier status, the
identity of the parent of origin cannot be disclosed, and
further clinical evaluation of the parents has been
postponed.
Mosaicism for Mutations in the TSC2 Gene
Family 3 (T5477).—The elder of two sisters had epi-
lepsy between the ages of 6 mo and 1 year. Subsequently
she was diagnosed with moderate mental retardation,
facial angiofibroma, white macules, a shagreen patch,
and an intracardiac tumor. A CT scan of the brain con-
firmed the diagnosis of TSC. Her younger sister had
epilepsy with severe mental retardation, facial angiofi-
broma, and ungual fibromas. She also had a cardiac
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Figure 2 RT-PCR products of cDNA clone containing the com-
plete coding region of the TSC2 gene (lane D), from fibroblasts of one
of the patients with TSC in family 4 (lane P), and from fibroblasts of
a negative control (lane C). N  normal RT-PCR fragment; A 
aberrant RT-PCR fragment.
tumor and renal angiomyolipoma. A CT scan of the
brain confirmed TSC in her as well. Their father ap-
peared to have facial angiofibroma, white macules, and
a shagreen patch on the skin, depigmentations of the
retina, angiomyolipoma of the kidney, and gingival fi-
broma of the mouth. He had no epilepsy or mental re-
tardation. In this family, SSCP analysis followed by di-
rect sequencing of intron–exon boundaries led to the
detection of a splice-site mutation 2374-2ArC in intron
20 of the TSC2 gene, present at a mosaic level in the
father. The effect of this splice-site mutation could not
be studied, because no RNA was available.
Family 4 (T1328).—The oldest son in this family had
facial angiofibroma, white macules, subependymal nod-
ules, and cortical tubers. Although he had suffered from
infantile spasms, he had normal intelligence. His brother,
14 mo younger, had facial angiofibroma, white macules,
subependymal nodules, and cortical tubers, with epi-
lepsy and mild mental retardation. He showed cardiac
rhabdomyoma and a single gingival fibroma. Facial an-
giofibroma and white macules were subsequently seen
in the father. A CT scan of his brain revealed subepen-
dymal nodules. He had no retardation or epilepsy. Mu-
tation analysis resulted in the identification of a splice-
site mutation 1561GrA in intron 1 of the TSC2 gene.
RT-PCR analysis, with primers located in exon 1 and
exon 2, resulted in the identification of an abnormal
fragment (fig. 2). Direct-sequence analysis of the aber-
rant fragment with the same primers showed the use of
a cryptic splice site in exon 1 at nucleotide position
105–106 (numbering according to The European Chro-
mosome 16 Tuberous Sclerosis Consortium 1993), caus-
ing a frameshift resulting in a stop codon at amino acid
position 31. This mutation was previously described in
another family (Kumar et al. 1997). The signal of the
mutant allele was clearly reduced in the father, shown
by ASO hybridization analysis, indicating somatic
mosaicism.
Family 5 (T3947).—This family was originally re-
ported as the first family with TSC showing somatic
mosaicism, proved by DNA analysis (Verhoef et al.
1995). A 4-year-old boy had epilepsy for 2 years and
multiple white macules. Periventricular subependymal
calcifications and cortical hypodensities were seen on his
CT scan, proving the diagnosis of TSC. The father
showed mild signs of TSC, with subtle facial angiofi-
broma, dental pits, and, on a CT scan, one paraventri-
cular calcified nodule, but no epilepsy or mental retar-
dation. A 1.5-kb deletion in the TSC2 gene was detected
with Southern blot analysis with marker 4.9E0.7 on
PvuII-digested DNA. A consistent difference in signal
intensities between normal and aberrant fragments dem-
onstrated somatic mosaicism in the father. This result
was confirmed from a newly collected blood sample.
Family 6 (T9703).—The index patient in this family
was a 2-year-old girl, given a diagnosis of TSC when
analyzed for her epilepsy. The parents were then
screened. The father was found to have ungual fibromas
and facial angiofibroma. A CT scan of the brain revealed
several subependymal nodules, and a renal CT scan
showedmultiple small angiomyolipomas. The father had
no history of epilepsy and had normal intelligence.
Southern blot analysis, with probes 4.9E0.7 and 4B2,
on DNA of the index patient indicated a deletion in the
TSC2 gene. Despite the use of a combination of different
restriction enzymes, the exact length of the deletion
could not be determined. Her father has a changed ratio
of normal to abnormal signals and carries somatic mo-
saicism. The clinical data on all individuals carrying the
mosaicism are summarized in table 2.
Discussion
In general, a high rate of mosaicism has been predicted
for conditions with a high percentage of new mutations
(Hall 1988) and has recently been demonstrated for an-
other tumor suppressor gene syndrome, neurofibroma-
tosis type 2 (Kluwe and Mautner 1998). Our results
indicate a level of gonadal and/or somatic mosaicism of
∼10% (6/62) in the group with TSC with a known mu-
tation. The true prevalence of mosaicism in our study
population of patients with TSC is probably higher than
the 10% (6/62) detected in the present study, because in
17 of the 62 families the parents were not investigated.
The proportion of sporadic patients with TSC with a
severe phenotype who are mosaic is unknown, as most
mutations in TSC are unique mutations, and a distinc-
tion between high-grade mosaicism and nonmosaicism
can be impossible. Conversely, a low level of mosaicism
in blood cells can be undetectable; thus, the mutation
will remain unidentified unless other tissues from the
patient are tested.
According to empirical, worldwide data on families
with TSC, the incidence of gonadal mosaicism in clin-
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Table 2
Clinical Signs of the Person Mosaic for the Mutation
VARIABLE












No. of affected children 1 3 3 2 2 1 1
Symptom or sign:b
Facial angiofibroma      / 
White macules   /    
CT-scan abnormalities  Unknown Unknown Unknown  / 
Intelligence Normal Normal Normal Normal Normal Normal Normal
Epilepsy       
a Both parents were clinically unaffected—but were incompletely examined.
b   Present;   absent; /  single symptom/minimal sign.
ically unaffected parents of children with TSC is
∼1%–2% (Berberich and Hall 1979; Baraitser and Pat-
ton 1985; Connor et al. 1986; Rott and Fahsold 1991;
Webb and Osborne 1991; Ruggieri et al. 1997). In our
study, one such family with mosaicism was detected as
a result of multiple affected offspring from healthy par-
ents. Gonadal mosaicism was proven by haplotype anal-
ysis, whereas the presence or absence of somatic mo-
saicism could not be investigated extensively. Gonadal
mosaicism was recently reported for TSC (Yates et al.
1997). Both in the family reported by Yates and in the
family we studied, it remains uncertain as to whether
the mosaicism was present in the gonads only or in other
tissues as well.
In all five persons in whom somatic mosaicism was
detected, the diagnosis of TSCwasmade in their children
first. Subsequent clinical investigations of the parents
showed that the mosaic parents did fulfill the diagnostic
criteria of TSC (Roach et al. 1992), although all these
parents had normal intelligence and no epilepsy.
For the individual with mosaicism, the risk for future
offspring to inherit the mutation is dependent on the
proportion of germ cells that contain the mutation. This
risk will be 50%, as has been shown for other con-
ditions (Zlotogora 1998). An exact estimate of the level
of mosaicism in the gonads is difficult to obtain, al-
though sperm analysis is technically possible. Siblings
and parents of a patient with proven mosaicism have a
population risk of a TSC mutation, because a mosaic
mutation is presumably a postzygotic event and thus
excludes gonadal mosaicism in one of the parents as a
source of the mutation.
Complete clinical screening of parents of seemingly
sporadic patients with TSC remains essential to exclude
the possibility of a mild phenotype of which parents are
not aware, to which somatic mosaicism might contrib-
ute. If parents do not show any signs of TSC at full
clinical evaluation (including a brain CT scan), the
chance of one of them having gonadal mosaicism would
be ∼2% (in our data set, one family in 45). A substan-
tially higher possible overall mosaicism figure (10% in
our data set) might need to be given until parents have
completed clinical investigations and have shown no
abnormalities.
Since low-degree somatic and gonadal mosaicism can
remain undetected in DNA from blood cells, we discuss
the low-percentage chance of gonadal mosaicism with
parents of a child with TSC seemingly due to a de novo
mutation and would be inclined to offer prenatal testing
for the mutation in a further pregnancy if requested by
the parents. In view of the serious consequences for ge-
netic counseling of families with TSC, a larger series of
mosaic and nonmosaic parents would be required, with
a more systematic genotype–phenotype analysis, to
show whether somatic mosaicism contributes to amilder
phenotype in TSC.
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